

Clark & Elbing LLP

101 Federal Street
Boston, MA 02110

Telephone 617-428-0200
Facsimile 617-428-7045
617-428-7046

Date: October 12, 2005
To: Examiner Teller
U.S. Patent and Trademark Office
Group Art Unit 1654
Facsimile No.: 571-273-8300
From: Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109
Re: U.S. Patent Application Serial No. 10/772,774
NOVEL ANTIARRHYTHMIC PEPTIDES
Larsen et al.
Filed: February 4, 2004
Attorney Docket No.: 50412/018003
Customer No. 21559
Pages: 3, including cover page.
Message: The following papers are enclosed:
Revocation and New Power of Attorney (2 pages)

RECEIVED
CENTRAL FAX CENTER

OCT 12 2005

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

Oct-12-05 05:47pm From:CLARK & ELBING LLP
16-10-03 10.04

+6174287045

T-111 P.002/003 F-505

RECEIVED
CENTRAL FAX CENTER

OCT 12 2005

PATENT
ATTORNEY DOCKET NO. 50412/018003

Certificate of Facsimile Transmission: Date of Transmission: 10-12-05

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to the Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450; Facsimile No. 571-273-8300.

JANET D'ANNUNZIO - ELLIS
Printed Name of Person Faxing Transmission

JANET D'ANNUNZIO - ELLIS
Signature of Person Faxing Transmission

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bjarne Due Larsen Art Unit: 1654
Serial No.: 10/772,774 Examiner: Teller
Filed: February 4, 2004 Customer No.: 21559
Title: NOVEL ANTIARRHYTHMIC PEPTIDES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION AND NEW POWER OF ATTORNEY

Under 37 C.F.R. § 3.73(b), Zealand Pharma A/S, a corporation, certifies that it is the assignee of 100% of the right, title, and interest in the patent application identified above by virtue of:

A chain of title from the inventors of the parent application, U.S. Serial No. 09/792,286, to the current assignee as shown below. Copies of the assignments or other documents in the chain of title are enclosed.

1. From Inventors Bjarne Due Larsen, Jorgen Søberg Petersen, Eddi Meier, Anne Louise Kjolbye, Niklas Rye Jorgensen, Morten Schak Nielsen, James B. Martins, and Niels-Henrik Holstein-Rathbun, to Zealand Pharmaceuticals A/S, as recorded in the Patent and Trademark Office at Reel 011864, Frame 0827, on June 6, 2001.
2. From Zealand Pharmaceuticals A/S to Zealand Pharma A/S, by a Change

BEST AVAILABLE COPY

of Name Certificate, as recorded in the Patent and Trademark Office at Reel 013152, Frame 0784, on August 5, 2002.

3. David Knott to Zealand Pharma A/S, as recorded in the Patent and Trademark Office at Reel 015142, Frame 0709, on March 29, 2004.

The present application is a continuation of U.S. Serial No. 09/792,286, and thereby this assignment is applied to the present application (M.P.E.P. §306).


The undersigned, acting on behalf of the assignee, hereby revokes all powers of attorney previously granted in the application and appoints the attorneys and/or agents of Clark & Elbing LLP, associated with customer number 21559, with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected therewith.

All correspondence regarding the application should be sent to the address associated with customer number 21559.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Date: 11/10/05


Zealand Pharma A/S

Eva Steilross
CFO

BEST AVAILABLE COPY